Connect Biopharma Holdings Ltd ADR (CNTB) Stock Price, Quote & News

Company Profile

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 877 245 2787

Website: www.connectbiopharm.com

Address:

3580 Carmel Mountain Road, Suite 200, San Diego, United States

stevie2times Jun. 24 at 12:43 AM

$CNTB Rademikibart is the only monoclonal antibody that whoops acute asthma ass inside 24hrs!! It's an untouched indication that will bring in $6B/$7B annually w o fkn competition. The Eczema data is sweet, But' it's a Bolt-on to acute asthma & COPD.

1 · Reply

mikeywo Jun. 23 at 1:46 PM

$CNTB does anyone have a quick comparison on atopic dermatitis results comparing Nektar and Connect ? I’m reading alot about Nektar being a possible takeover target now.

7 · Reply

elmono Jun. 22 at 11:29 PM

$CNTB this is ageing nicely. Company suddenly changing narrative of 1 month ago when they expected read out in mid 2026. Incompetence or Lying…..which of the 2 is it 😂😂😂

2 · Reply

elmono Jun. 22 at 11:26 PM

$CNTB 1 month ago in May they stated: “ Expect to report topline data from both Phase 2 Seabreeze STAT studies mid-2026 –“ …..no they say September. Conclusion: crap management. Not in control of timelines, no clue about clinical trials, or simply lying in May. Under normal circumstances this change of narrative is enough to get you fired. Now it is just a huge red flag, combined with all selling of the last 2 months. Someone always knows. This will not end well

1 · Reply

elmono Jun. 22 at 11:15 PM

$CNTB last 2 months only selling ….bodes well. Me thinking large ass offering incoming 😂😂😂

1 · Reply

BennyBoy18 Jun. 22 at 9:42 PM

$CNTB I will let James Huang , the insider buying dude clap my girlfriends cheeks if this touches $16

0 · Reply

mikeywo Jun. 22 at 8:07 PM

$CNTB If $CTNB has superior efficacy and safety to $APGE in the atopic dermatitis arena and can compete with Dupixent in the Asthma space obviously the market does not know this yet and obviously $ABBV didn’t know it either or why pay 10B for a company that drug is going to be second choice behind Rademikibart. It’s time Barry either resigns or gets off his ass and find people who can get this drug known to the big players and analyst who control the bio market. 124M market cap is absolutely ridiculous.

3 · Reply

Hawksssss Jun. 22 at 11:32 AM

$CNTB wonder who is doing this pre market thing. It is up 3-4% pre market everyday.

1 · Reply

Teshuvah Jun. 21 at 4:12 PM

$CNTB up about 20 watchers in past couple of days

0 · Reply

stevie2times Jun. 21 at 6:08 AM

$CNTB This Abbvie news has Sanofi, Eli Lilly, & Novartis full attn right here. Quicker response ✅ Clean Safety profile ✅ (3% to 6% Conjunctivitis compared to Apogee 10% to 13%) Efficacy ✅ Rademikibart already posted up Ph3 96.6% EASI 75 after 52wks & 85.3% EASI 90 after 52wks

2 · Reply

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

2026-05-26T09:25:05.000Z - 4 weeks ago

Connect Biopharma initiated with a Buy at Canaccord

2026-05-21T10:41:51.000Z - 4 weeks ago

Connect Biopharma initiated with an Overweight at Cantor Fitzgerald

2026-05-21T10:11:38.000Z - 4 weeks ago

Connect Biopharma initiated with an Overweight at Cantor Fitzgerald

May 19, 2026, 9:30 AM EDT - 5 weeks ago

Connect Biopharma Holdings Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-15T15:43:54.000Z - 5 weeks ago

Connect Biopharma files to sell 6.13M ordinary shares for holders

May 15, 2026, 8:00 AM EDT - 5 weeks ago

Connect Biopharma Holdings Registration statement: Registration filing

May 14, 2026, 7:00 AM EDT - 5 weeks ago

Connect Biopharma Holdings Slides: Corporate presentation

May 12, 2026, 4:05 PM EDT - 6 weeks ago

Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 9:00 AM EDT - 6 weeks ago

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 9:00 AM EDT - 6 weeks ago

Connect Biopharma Holdings Earnings release: Q1 2026

May 12, 2026, 9:00 AM EDT - 6 weeks ago

Connect Biopharma Holdings Quarterly report: Q1 2026

2026-04-23T13:29:20.000Z - 2 months ago

Connect Biopharma announces enrollment in Seabreeze STAT study

Apr 23, 2026, 9:00 AM EDT - 2 months ago

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

2026-04-01T21:15:48.000Z - 3 months ago

Connect Biopharma director buys $4.0M in common stock

Mar 31, 2026, 4:05 PM EDT - 3 months ago

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

Mar 31, 2026, 4:00 PM EDT - 3 months ago

Connect Biopharma Holdings Annual report: Q4 2025

Mar 31, 2026, 4:00 PM EDT - 3 months ago

Connect Biopharma Holdings Earnings release: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Connect Biopharma Holdings Transcript: Study result

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Connect Biopharma Holdings Press release: Study result

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Connect Biopharma Holdings Slides: Study result

2026-03-30T11:26:39.000Z - 3 months ago

Connect Biopharma announces results from rademikibart study

Mar 30, 2026, 7:02 AM EDT - 3 months ago

Connect Biopharma Announces $20.2 Million Private Placement Financing

Mar 30, 2026, 7:01 AM EDT - 3 months ago

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

Mar 10, 2026, 9:00 AM EDT - 3 months ago

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Connect Biopharma Holdings Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Connect Biopharma Holdings Slides: FY 2026

Mar 3, 2026, 9:00 AM EST - 4 months ago

Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference

Feb 26, 2026, 2:40 PM EST - 4 months ago

Connect Biopharma Holdings Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 9:00 AM EST - 4 months ago

Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-12T13:27:00.000Z - 5 months ago

Connect Biopharma highlights new mechanism of action data for rademikibart

Jan 12, 2026, 8:00 AM EST - 5 months ago

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

Jan 12, 2026, 7:00 AM EST - 5 months ago

Connect Biopharma Holdings Slides: Corporate presentation

2026-01-05T16:45:30.000Z - 6 months ago

H.C. Wainwright names two best 2026 ideas in SMID-cap biopharma

ACHV

Dec 2, 2025, 10:50 AM EST - 7 months ago

Connect Biopharma Holdings Transcript: Evercore ISI 8th Annual HealthCONx Conference

2025-12-01T13:45:55.000Z - 7 months ago

Connect Biopharma initiated with a Buy at Lake Street

Nov 24, 2025, 9:00 AM EST - 7 months ago

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 9:00 AM EST - 8 months ago

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 9:00 AM EST - 8 months ago

Connect Biopharma Holdings Quarterly report: Q3 2025

Nov 12, 2025, 9:00 AM EST - 8 months ago

Connect Biopharma Holdings Earnings release: Q3 2025

Nov 3, 2025, 4:15 PM EST - 8 months ago

Connect Biopharma Holdings Transcript: Status Update

2025-10-31T10:10:32.000Z - 8 months ago

Connect Biopharma initiated with a Buy at BTIG

2025-09-29T13:21:17.000Z - 9 months ago

Connect Biopharma presents data on rademikibart at ERS Congress

Sep 29, 2025, 9:00 AM EDT - 9 months ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

Sep 8, 2025, 9:30 AM EDT - 10 months ago

Connect Biopharma Holdings Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 10 months ago

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 3, 2025, 3:20 PM EDT - 10 months ago

Connect Biopharma Holdings Transcript: Cantor Global Healthcare Conference 2025

2025-09-03T12:05:15.000Z - 10 months ago

Connect Biopharma completes termination of ADR program, lists on Nasdaq

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

Aug 27, 2025, 9:00 AM EDT - 10 months ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in September

2025-08-14T12:26:40.000Z - 11 months ago

Connect Biopharma patners with Ickey Woods, Jovante Woods Foundation

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

Aug 13, 2025, 9:00 AM EDT - 11 months ago

Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 9:00 AM EDT - 11 months ago

Connect Biopharma Holdings Quarterly report: H1 2025

Aug 13, 2025, 9:00 AM EDT - 11 months ago

Connect Biopharma Holdings Earnings release: H1 2025

Jul 22, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Jul 21, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

Jul 18, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

Jul 17, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 13, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Connect Biopharma Holdings Registration statement: Registration Filing

Jun 5, 2025, 8:10 AM EDT - 1 year ago

Connect Biopharma Holdings Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Holdings Transcript: Noble Capital Markets Emerging Growth Virtual Equity Conference

Jun 3, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Connect Biopharma Holdings Slides: Corporate Presentation

May 28, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma to Present at Two Upcoming Investor Conferences in June

May 20, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

May 15, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Holdings Quarterly report: Q1 2025

May 15, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Holdings Earnings release: Q1 2025

May 14, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

May 13, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

Apr 1, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

Mar 31, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

Mar 31, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Holdings Earnings release: H2 2024

Mar 31, 2025, 9:00 AM EDT - 1 year ago

Connect Biopharma Holdings Annual report: H2 2024

Mar 28, 2025, 4:05 PM EDT - 1 year ago

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Mar 27, 2025, 2:30 PM EDT - 1 year ago

Connect Biopharma Holdings Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 1:40 PM EDT - 1 year ago

Connect Biopharma Holdings Transcript: Leerink’s Global Healthcare Conference 2025

Mar 3, 2025, 8:00 AM EST - 1 year ago

Connect Biopharma to Present at Two Upcoming Investor Conferences

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Attovia Therapeutics Appoints Chief Financial Officer

Oct 9, 2024, 3:55 PM EDT - 1 year ago

CNTB Stock Dips Amid Biotech Sector Volatility

Oct 2, 2024, 4:14 PM EDT - 1 year ago

CNTB Stock Surges Over 5% Amid Strong Financial Performance

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

Sep 5, 2024, 4:00 PM EDT - 1 year ago

Connect Biopharma Holdings Quarterly report: H1 2024

Aug 6, 2024, 2:00 AM EDT - 2 years ago

Connect Biopharma Holdings Slides: Corporate Presentation

Jul 1, 2024, 8:00 AM EDT - 2 years ago

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Jun 12, 2024, 6:03 PM EDT - 2 years ago

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2024, 4:15 PM EDT - 2 years ago

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

May 22, 2024, 4:05 PM EDT - 2 years ago

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

May 7, 2024, 6:30 AM EDT - 2 years ago

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Apr 16, 2024, 4:05 PM EDT - 2 years ago

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Apr 16, 2024, 4:00 PM EDT - 2 years ago

Connect Biopharma Holdings Annual report: H2 2023

Apr 16, 2024, 4:00 PM EDT - 2 years ago

Connect Biopharma Holdings Quarterly report: H2 2023

Mar 19, 2024, 8:30 AM EDT - 2 years ago

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

Feb 12, 2024, 4:30 PM EST - 2 years ago

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

Dec 12, 2023, 8:30 AM EST - 2 years ago

Connect Biopharma Holdings Transcript: Study Result

Dec 12, 2023, 8:30 AM EST - 2 years ago

Connect Biopharma Holdings Press release: Study Result

Dec 12, 2023, 8:30 AM EST - 2 years ago

Connect Biopharma Holdings Slides: Study Result

Dec 12, 2023, 6:00 AM EST - 2 years ago

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

stevie2times Jun. 24 at 12:43 AM

1 · Reply

mikeywo Jun. 23 at 1:46 PM

$CNTB does anyone have a quick comparison on atopic dermatitis results comparing Nektar and Connect ? I’m reading alot about Nektar being a possible takeover target now.

7 · Reply

elmono Jun. 22 at 11:29 PM

$CNTB this is ageing nicely. Company suddenly changing narrative of 1 month ago when they expected read out in mid 2026. Incompetence or Lying…..which of the 2 is it 😂😂😂

2 · Reply

elmono Jun. 22 at 11:26 PM

1 · Reply

elmono Jun. 22 at 11:15 PM

$CNTB last 2 months only selling ….bodes well. Me thinking large ass offering incoming 😂😂😂

1 · Reply

BennyBoy18 Jun. 22 at 9:42 PM

$CNTB I will let James Huang , the insider buying dude clap my girlfriends cheeks if this touches $16

0 · Reply

mikeywo Jun. 22 at 8:07 PM

3 · Reply

Hawksssss Jun. 22 at 11:32 AM

$CNTB wonder who is doing this pre market thing. It is up 3-4% pre market everyday.

1 · Reply

Teshuvah Jun. 21 at 4:12 PM

$CNTB up about 20 watchers in past couple of days

0 · Reply

stevie2times Jun. 21 at 6:08 AM

2 · Reply

Hawksssss Jun. 20 at 2:00 AM

$APGE $CNTB Perceptive is a shareholder in both of these two companies. Perceptive is one of the most successful bio specialist fund. They are in almost every BO this year including Nuvalent, Centessa, Amicus, Merus, and Verona (same sector as apogee and Connect) Eli Lily currently owns 5% of Connect Good luck

0 · Reply

Hawksssss Jun. 20 at 1:48 AM

$CNTB $APGE 1of 2) I used AI to compare Connect’s phase 3 China results with those of Apogee’s. Apogee has advantage in terms of dosing regime while Connect has superior efficacy and safety profile. Dosing frequency • Rademikibart: Regular every 2–4 weeks • Zumilokibart: Only 4 injections for 16-week induction, maintenance every 3–6 months

0 · Reply

Hawksssss Jun. 20 at 1:46 AM

$APGE $CNTB 2of 2 Brief Clinical Outcome Comparison between Connect China phase data and Apogee Efficacy (Week 16) 1. EASI-75: Rademikibart higher (74.2%) vs Zumilokibart (65.9%) 2. IGA 0/1 clearance: Nearly equal (Rademikibart 47.7% / Zumilokibart 46.0%) 3. EASI-90 deep clearance: Zumilokibart slightly better (47.4%) vs Rademikibart (43.0%) 4. Itch reduction: Rademikibart superior (54.7%) vs Zumilokibart (50.5%) Long-term 52-week maintenance • Rademikibart: Very high sustained response (EASI-75 96.6%, IGA 0/1 87.1%) with Q2W/Q4W dosing • Zumilokibart: 85% Week 16 responders kept EASI-75 with semi-annual ultra-long dosing Safety • Rademikibart: Lower conjunctivitis rate (3.9%) and mild overall adverse event rate • Zumilokibart: Higher conjunctivitis risk (10.6%–20.7% across doses); comparable general adverse event profile otherwise Onset speed • Rademikibart: Noticeable relief at Week 1 • Zumilokibart: Itch relief within 48 hours

0 · Reply

stevie2times Jun. 20 at 1:45 AM

$APGE $11B 😂 $CNTB is streets clear in Efficacy & Safety across the immuno pipeline!!

1 · Reply

Hawksssss Jun. 19 at 11:46 PM

$CNTB @mikeywo $APGE Mike, check out Apogee. In the same area as Connect. But our results trumped them big time. Their EASI-75 is only 65% while ours is 96.6%. Apogee is getting bought for 11 billion (rumor has it)

1 · Reply

mikeywo Jun. 19 at 12:24 PM

$CNTB patience will pay off as this becomes the new SOC for acute asthma , Chronic asthma and copd along with atopic dermatitis. 1500 patients have been treated in the U.S. and China with side effects no worse then placebo. Dupixent brings in 18B a year and if you’ve seen the commercials the list of serious side effects are numerous. What we need is the crooked market makers to value the drug and the company properly as the data comes in their fall and approvals are awarded in China. No one else is developing a drug for these indications so there is no competition. Barry has sold small bios to big pharma in the past and will Do it here also. All we can do is hope he navigates the next 2-3 years properly and cashes in at the end. If Dupixent brings in 18B$ a year and might be replaced by Radamikibart what does that value connect bio as a buyout ?

2 · Reply

Tomakak Jun. 18 at 1:23 PM

$CNTB could drop to 1.5, still better wait for at least a week after p2 results in september.. i will wait...

0 · Reply

BennyBoy18 Jun. 18 at 10:47 AM

$CNTB $16 is my dream fantasy target but will probbaly crash to 0.5 because i bought. Lol

0 · Reply

stevie2times Jun. 18 at 2:53 AM

$CNTB The license deal for Eczema on the back of that sweet Ph3 data from Mar 30th will be the nxt catalyst. J&J, Abbvie, or Eli Lilly most likely. J&J bought Numba Therapeutic for $1.25B & axed the eczema trial in Dec for futility 😭 They want in this space & Rademikibart is a hell of a way to ENTER.

1 · Reply

prismmarketview Jun. 17 at 5:46 PM

Connect Biopharma ( $CNTB ) has fully enrolled Seabreeze STAT Asthma (Phase 2), a randomized, placebo‑controlled study of rademikibart given on top of standard care during an asthma flare to cut treatment failures over 28 days. Milestone locked, now the wait is for readout. #CNTB #smallcap #immunology #biopharma https://x.com/PrismMarketView/status/2067302551972708454?s=20

0 · Reply

Hawksssss Jun. 17 at 2:50 PM

$CNTB what’s 3 months if this can do 100x (dreaming). If the drugs are as good as the China data show and they execute correctly, it is possible to be a multi bagger

1 · Reply

Hawksssss Jun. 17 at 2:41 PM

$CNTB so we have to wait for three more months for the readouts. Why did they say mid year in March. This is not how you build credibility with investors.

1 · Reply

Market Cap	125.30M
Revenue (ttm)	60,000.00
Net Income (ttm)	-55.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-92,466.67%
Debt to Equity Ratio	0.00

Volume	311,600
Avg Vol	249,460
Day's Range	N/A - N/A
Shares Out	62.96M
Stochastic %K	56%
Beta	-0.22
Analysts	Strong Sell
Price Target	$7.07